Drug
BP102
BP102 is a pharmaceutical drug with 6 clinical trials. Currently 1 active trials ongoing.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/2)
Active Trials
1(17%)
Terminated
2(33%)
Phase Distribution
Ph phase_1
2
33%
Ph phase_2
4
67%
Phase Distribution
2
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
4(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 2 finished
Non-Completion Rate
100.0%
2 ended early
Currently Active
1
trials recruiting
Total Trials
6
all time
Status Distribution
Active(4)
Terminated(2)
Detailed Status
Not yet recruiting3
Terminated2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
1
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (33.3%)
Phase 24 (66.7%)
Trials by Status
not_yet_recruiting350%
recruiting117%
terminated233%
Recent Activity
1 active trials
Showing 5 of 6
not_yet_recruitingphase_2
An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer
NCT07061210
recruitingphase_1
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
NCT06754930
not_yet_recruitingphase_2
SHR-1701 Combined with SHR2554 and BP102 for MCRC
NCT06679673
not_yet_recruitingphase_1
SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer
NCT06373133
terminatedphase_2
A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC
NCT03666728
Clinical Trials (6)
Showing 6 of 6 trials
NCT07061210Phase 2
An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer
NCT06754930Phase 1
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
NCT06679673Phase 2
SHR-1701 Combined with SHR2554 and BP102 for MCRC
NCT06373133Phase 1
SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer
NCT03666728Phase 2
A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC
NCT03645876Phase 2
SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6